CClinicalTrials.gg
Status unknownNCT05043818Updated Sep 14, 2021

A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression

An observational study in Inflammatory Bowel Diseases, sponsored by Third Military Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-09-14.

Sponsored by Third Military Medical University · Observational

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
178
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Inflammatory bowel disease (IBD) seriously affects the quality of life of patients. During treatment, it is found that patients are often accompanied by a certain degree of psychological problems, such as depression, sensitivity, introversion, depression, and pessimistic disappointment. Among them, anxiety and depression are the most common. Through prospective observational research, statistics of the incidence of depression in inflammatory bowel disease in our hospital, comparison of the proportions of each subtype, screening of intestinal biomarkers in IBD patients with depression, and observation of inflammatory bowel disease with different The type and quantity of different intestinal flora in patients with severe depression, and the correlation between intestinal flora and depression.

Read the detailed description

The subjects voluntarily participated in the study and signed an informed consent form. Follow the steps below:

  1. When you come to the hospital or the first to second days of admission, collect general information: ID number, gender, age, height, weight, BMI, complete medical history including a) date of diagnosis, b) degree of disease, c) course of disease , D) previous surgery, e) previous hospitalization, f) comorbidities, g) current symptoms, h) extra-articular manifestations, i) endoscopic data, j) treatment drugs and other data.
  2. Scale evaluation (see Annex 1 for details): Screening related scales for anxiety and depression symptoms (PHQ9, SDS, HADS, HAMA, HAMD), inflammatory bowel disease quality of life scale (IBDQ), ulcerative colitis Patient's modified Mayo score/Simplified questionnaire surveys for patients with Crohn's disease such as CDAI score, stool characteristics, abdominal pain degree, and Gastrointestinal Symptom Scale (GSRS);
  3. Stool specimens were collected once during the visit to the hospital.
  4. The time, frequency and precautions for patients to go to the hospital for examination and follow-up.

This trial is a prospective observational study. When the patient comes to the hospital or on the first to the second day of admission, the subject will be given a full set of scales to check once, and a stool sample will be collected during the treatment. Co., Ltd. performed 16S rRNA sequencing to analyze the results of the bacterial flora once. In this study, there is no need for patients to come to the hospital for follow-up follow-up.

02

Conditions studied

  • Inflammatory Bowel Diseases

Keywords

  • Ulcerative Colitis, Crohn's Disease,Anxiety , Depression
03

In context

Inflammatory Bowel Diseases

1,460 studies on the registry are indexed under Inflammatory Bowel Diseases; 437 are open to participants now.

This study's planned enrollment of 178 is above the median of 139 across 645 observational studies indexed under Inflammatory Bowel Diseases.

Browse Inflammatory Bowel Diseases studies →

Lead sponsor

Third Military Medical University is the lead sponsor of 81 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with inflammatory bowel disease diagnosed in the outpatient clinic or hospitalization of our hospital

Inclusion criteria

  1. Definite diagnosis of inflammatory bowel disease【diagnostic criteria reference: (2020)JSGE Evidence-based clinical practice guidelines: inflammatory bowel disease】
  2. There is no restriction on men and women, aged 18-65 years old;
  3. No complicated other serious diseases such as heart, brain, lung, liver, kidney, etc., no mental illness, and normal communication skills;
  4. No antibiotics, Bifidobacterium, Bacillus subtilis and other probiotic preparations have been used within one month;
  5. Sign the informed consent form and agree to participate in this research.

Exclusion criteria

Exclusion Criteria:

  1. Course of disease \<6 months;
  2. Unspecified inflammatory bowel disease.
  3. Authors with bipolar disorder, persistent mood disorder, and mania;
  4. Patients with malignant tumors;
  5. Patients during pregnancy and lactation;
  6. Combined with hypertension, diabetes, heart disease, stroke or severe chronic disease (infectious, genetic, metabolic, internal Secretory diseases);
  7. Patients who cannot cooperate to complete the study.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
178 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • IBD patients with depression

    IBD patients with depression

  • IBD patients without depression

    IBD patients without depression

06

What researchers measure

Primary outcomes

  1. PHQ-9 score

    Patient Health Questionnaire-9. The score varies from 0 to 27, higher scores suggest more severe the depression.Total score is the sum of 9 corresponding numbers: 0-4 points: no depression; 5-9 points: mild depression; 10-14 points: moderate depression; 15-27 points: severe depression.

    Time frame: 0 week

Secondary outcomes

  1. SDS score

    Self-rating Depression Scale. The score varies from 25 to 100. Higher scores suggest more severe depression.

    Time frame: 0 week

  2. HAMA-score

    Hamilton Anxiety Scale.The total score is 0-56, among which, physical anxiety: 7-13 items; mental anxiety: 1-6 and 14 items.The higher the score, the greater the anxiety.

    Time frame: 0 week

  3. HAMD-score

    Hamilton Depression Scale.The total score is 0-35 points: \>35 points: severe depression; \>20 points: mild or moderate depression; 8-20 may have depression; \<8 points: no depression. The higher the score, the greater the anxiety.

    Time frame: 0 week

  4. HADS-score

    Hospital Anxiety and Depression Scale.It consists of 14 (7 anxiety and 7 depression-related) scoring items, all ranging from 0-21. The higher the score, the more severe the anxiety and depression.

    Time frame: 0 week

  5. GSRS-score

    Gastrointestinal Symptom Rating Scale. The score varies from 16 to 112. High scores suggest more severe Gastrointestinal pathology.

    Time frame: 0 week

  6. Simplified CDAI score

    Simplified CDAI score for Crohn's disease: represents disease activity, \<4 remission period 5\~8 moderate activity\> 9 heavy activity. The higher the score, the more severe the condition.

    Time frame: 0 week

  7. Modified Mayo score for UC

    Modified Mayo score for ulcerative colitis: a total of 0-12 points, scores ≤ 2 points and no single sub-item score\> 1 points to clinical remission, 3 to 5 points to mild activity, 6 to 10 points to moderate activity, 11 \~12 is divided into heavy activity.

    Time frame: 0 week

  8. IBD-QoL

    Quality of Life Analysis Table for Patients with Inflammatory Bowel Disease: There are 32 questions in total. Each question has a different level of answer from 1 to 7, 1 generation The table has the heaviest degree, and 7 represents the least degree.

    Time frame: 0 week

Other outcomes

  1. Intestinal flora

    Use metagenomics technology to detect intestinal flora.

    Time frame: 0 week

07

Study locations

1 site
  • Department of Gastroenterology, Daping Hospital, The Third Military Medical University
    Chongqing, Chongqing 400042, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05043818
Lead sponsor
Third Military Medical University
Responsible party
Yanling Wei (Yanling Wei Deputy Chief Physician, Third Military Medical University) — Principal investigator
First posted
Sep 14, 2021
Start date
Sep 2021 (estimated)
Primary completion
Sep 2022 (estimated)
Completion
Sep 2022 (estimated)
Last update
Sep 14, 2021

Study contacts

Yanling Wei, MD
Contact
Lingzi016@126.com
15310354666
Yanling Wei, MD
principal investigator · Army Medical Center of PLA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion